Owkin’s Post

Epigene Labs is thrilled to announce we will be presenting a poster at the 2024 ESMO - European Society for Medical Oncology's Targeted Anticancer Therapies Congress next week in Paris. Our poster, “A machine learning-powered dashboard for the exploration of high-throughput transcriptomic datasets” describes how we use novel AI models to unlock the potential of large data repositories, such as GEO database. The result: We identified the top 10% most relevant transcriptomic datasets for precision oncology R&D. Camille Marijon, Charles Lescure, Solène Weill, and Valentin Bernu from the Epigene Labs team will be on-site to present and discuss our findings. Get ready to take secondary analysis of cancer omic data to the next level! Our mission is at Epigene Labs to revolutionize oncology R&D with omic data and AI. The ESMO TAT Congress provides a space for academics, industry leaders, researchers, investors, and regulators to collaborate and discuss advancements in precision oncology. We're honored to contribute our insights and innovative approaches to the future of cancer treatment at this event. If you're attending, we invite you to visit our poster and learn more about Epigene Labs and our work to make a meaningful impact in the fight against cancer. https://lnkd.in/ejDXNbmc #ESMOTAT #ESMO #Innovation #AI #PrecisionOncology

A concrete application and implication of 10x Genomics in Cancer diagnostic!

Looking forward to presenting at the Labroots and Vizgen webinar! Register to learn how we at Compugen utilize MERFISH technology to study the nuances of the complex human tumor microenvironment at a spatially resolved single-cell level 🔬 #innovation #computationalbiology #immunooncology #SpatialTranscriptomics #webinar

🌟 Exciting News in Cancer Research! 🌟 🔬 Pangea Biomed is partnering with Hadassah Medical Center and Ultima Genomics to revolutionise solid tumor cancer treatment at the Sharett Oncology Institute. 🏥💡 📈 Highlights: -Advanced Profiling: Using comprehensive DNA, RNA, and imaging data to enhance treatment predictions for solid tumors. -Innovative Tools: FoundationOne for genetic profiling and ENLIGHT’s AI-driven platform for personalized treatment. -Expert Collaboration: Hadassah’s oncologists providing essential samples and analysis. 🌍 Goals: -Improve treatment accuracy and effectiveness. -Create an unparalleled dataset for research. -Generate ENLIGHT reports for over 2,000 patients annually. 📢 Leaders’ Insights: Tuvik Beker, CEO of Pangea Biomed: "A significant step forward in fighting solid tumors." Prof. Aron Popovtzer: "Combining clinical expertise and advanced technology for precise treatments." #CancerResearch #PrecisionOncology #Genomics #AIinHealthcare #MedicalInnovation #SolidTumors #PangeaBiomed #Hadassah #UltimaGenomics #HealthcareRevolution #Oncology

🔬✨ Join us for an insightful session on "Outsmarting Cancer with Light" with the esteemed Dr. Samuel Achilefu. Embark on an enlightening journey with us during "Outsmarting Cancer with Light," a highlight of the STRECH (Seminars in Translational Research) series. This seminar is set to explore groundbreaking methods of employing light in the detection and treatment of cancer. 🧬 🗓️ Mark your calendars for Friday, February 16, 2024 ⏰ Join us from 9:00 AM to 10:00 AM (virtually) for an innovative session that promises to reshape our understanding and approach towards conquering cancer. We're honored to have Dr. Samuel Achilefu, PhD, Professor and Chair at the University of Texas Southwestern Medical Center, as our distinguished speaker! 🎉 Dr. Samuel Achilefu will unveil his pioneering work on a signal-amplifying pancancer molecule designed to enhance the visualization and eradication of tumors during surgical procedures. The seminar will also spotlight the encouraging findings from preclinical studies and ongoing phase 1 clinical trials, underscoring the potential to dramatically improve surgical outcomes. Seize this unique chance to be at the cutting edge of biomedical breakthroughs. Whether you're a student, professional, or simply a curious mind passionate about making a difference in healthcare, this seminar is set to inspire and inform. For further information and to be a part of this transformative seminar, please visit our website at https://lnkd.in/gR7Q-4Xi #CancerResearch #BiomedicalEngineering #Innovation #STRECH #UTHealth #UTSA

NFCR would like to congratulate io9 Inc. for being named one of the hottest life sciences companies in Southern California by Connect, the Southern California technology industry group. io9 was one of 15 life science companies selected from hundreds of applicants. Among the co-founders, Dr. Webster Cavenee is Chair of the NFCR Scientific Advisory Board and the 2007 winner of the Szent-Györgyi Prize for Progress in Cancer Research. Another co-founder, Dr. Scott Lippman, also serves on the Scientific Advisory Board for NFCR. Both Dr. Cavenee and Dr. Lippman are renowned cancer research leaders. io9 is developing a novel approach and platform in the fight against cancer, utilizing breakthrough artificial intelligence digital pathology developed by another of io9’s co-founders, Dr. Ludmil Alexandrov. The io9 technology determines biomarkers for oncology therapy selection from slides that are commonly used for cancer diagnosis, thus resulting in earlier front-line therapy implementation. Their technology can tremendously cut the processing time for identifying necessary treatments, leading to better treatment solutions and more lives saved. This is a critical approach needed to impact patient treatment options and outcomes. #ai #innovation #venture #nfcr #makecurespossible #groundbreaking #digital #congratulations #leading #investmentinthefuture #cancer #research #cancerresearch Greg Hamilton

The intersection of immunogenomics, bioinformatics, and AI is transforming the landscape of cancer immunotherapy. The development of neoantigen discovery tools is a testament to this progress, offering new hope for personalized treatment strategies. As we continue to push the boundaries of science and technology, let's celebrate the advancements in neoantigen prediction and its promise for precision medicine. The journey is far from over, but each step brings us closer to a future where cancer treatment is as unique as the individuals it serves p/b Paul-Ehrlich-Institut, Johannes Gutenberg University Mainz, Alla Bulashevska, Martin Machyna, Mustafa Diken #Immunotherapy #Bioinformatics #Artificialintelligence https://lnkd.in/gQTzMm3k

Welcome back to ENJOY Science webinar at MD Anderson Cancer Center Fall 2024 session and get CME credits! Thursday September 5th at 10AM CST Dr Jinsong Liu, MD, PhD talk on "Decoding the Enigma of Cancer Complexity through the Lens of Giant Cells". This series now offers AMA PRA Category 1 CreditsTM . The texting portal to claim credit opens 15 minutes before the start of the presentation and will remain open for the duration of the seminar and up to 24 hours after the session has ended. https://lnkd.in/gdnp7X3f Step 1: Create/Access your PEP@MD Anderson Account and Profile A. Go to https://lnkd.in/gNgw67DZ B. Click "Sign In" on the top left C. Select the login option appropriate to your situation: • If you are an MD Anderson employee, log in with your MD Anderson email address and password ("MD Anderson Login"), following the prompts to provide required information. Then skip to Step 2 (Pair Your Mobile Number to PEP) • If you are external to MD Anderson, choose the 2nd option – “Guest Login" D. If you are external to MD Anderson and you have never logged into the system before, you’ll need to click on “Don’t have an account?” E. After completing all of the required fields, select the “Create Account” button. F. Log in with the email and password you just specified and click the "My CE" button on the top right‐hand side of the screen. G. When the MyCE dashboard displays, select the “Profile” icon. Step 2: Pair Your Mobile Number to PEP These instructions below assume that you have an active account in PEP@MD Anderson and that you have entered a working mobile phone number. If you do not have an account, please return to Step 1 (Create/Access your PEP@MD Anderson Account and Profile). A. One‐time process: Pair the mobile app with your phone 1. Text the email address you entered in your Profile, to 844‐912‐1333. 2. You will receive a message that looks like the one below. Recommendation: Save the number 844‐912‐1333 in your cell phone contacts list so that you can easily identify the number for future attendance texting. “MD Anderson PEP” is one suggestion. B. One‐time process (optional): Download the CloudCME mobile app The CloudCME app allows you to check in for an activity, complete an evaluation, claim credit, view content, and see listings of activities on your mobile device. (Downloading the app is not required for texting attendance.) 1. Navigate to your smart phone’s app store and search for CloudCME. 2. When prompted for the organizational code, enter: MDAnderson (no spaces). You will log in to the app with the same email and password you use to sign in to PEP@MD Anderson. Step 3: Text Attendance During/After a CE Activity A. An Activity ID will be announced at the start of your event. B. Send a text with that activity ID to 844‐912‐1333. You will receive a text message confirming your attendance has been recorded.

What does the future of #oncologyresearch look like? 👇 👇 👇 🌐 Join us for Evident Life Science's Exclusive Webinar on "Spatial Transcriptomics in Colon Cancer Research" with Professor Amin El-Heliebi and Dr. Laura Lleras Forero. Gain insights into cutting-edge cancer research using imaging-based in situ sequencing methods with sub-cellular resolution, powered by our very own #VS200 digital slide scanner and #Cartana probes from 10x Genomics. 📅 Date: Feb 8 ⏰ Time: 4-5 p.m. CET 💡 This webinar is a must-attend for those interested in tumour biology, biomarkers, drug discovery, and cancer research. Join us to learn about the latest advancements in microscopy and pathology and discover new ways to approach cancer research.💡 🔗 Register now: https://lnkd.in/guCcMvYt #EvidentLifeScience #spatialtranscriptomics #coloncancer #VS200 #10XGenomics #cancerresearch #Cartana #insitu #tumour #biomarkers #cancer #microscopy #pathology #drugdiscovery #lifescience

Following up on my previous post about my journey into the fascinating world of genomics, I’ve come to realize the importance of a hook—something that captivates your interest and keeps you engaged. This concept was familiar to me from homeschooling my children, where I emphasized the importance of a compelling start in storytelling. It turns out, the same principle applies to podcasts. I recently experienced this firsthand while listening to a conversation between Cara and Erica, which concluded with an intriguing question: "If given a magic wand, what would you wish for?" The answer—molecular tumor boards for every patient—struck a chord with me and brought back memories of my time at VCU (Virginia Commonwealth University) in the Radiation Oncology department. I vividly recall attending tumor board meetings where critical patient cases were discussed by a multidisciplinary team, including medical, radiation, and surgical oncologists. At the time, much of the conversation went over my head, but I now see how crucial these interdisciplinary discussions are for devising the best treatment strategies. Cancer is inherently an interdisciplinary disease, requiring the collaboration of various specialists to navigate a patient's journey toward the best possible prognosis. In today’s era, molecular tumor specialists play a vital role in helping physicians leverage biomarker and genomic information to enhance patient care. A wise colleague once told me, “You can’t call yourself an oncology domain expert without delving deep into genomics.” With that in mind, my quest to deepen my understanding of genomics continues, fueled by podcasts and other educational resources. #Cancer #Oncology #Interdisciplinary #Genomics